title: Use of high-resolution volumetric MR spectroscopic imaging in assessing treatment response of glioblastoma to an HDAC inhibitor.
abstract: OBJECTIVE
  Improved predictive imaging would enable personalization and adjustment of treatment, which are critical for patients with glioblastomain whom therapy is likely to fail. This article describes the use of MR spectroscopic imaging (MRSI) to predict early clinical and behavioral response to a therapy and an effort to develop high-resolution, volumetric MRSI to improve its clinical application.
  
  
  CONCLUSIONS
  MRSI may enable quantitative analysis of brain tumor response, offering a precise tool for monitoring of patients in clinical trials.
authors: 1 Department of Radiology and Imaging Sciences, Emory University, 1701 Uppergate Dr, C5018, Atlanta, GA 30322.
authors: Hyunsuk
authors: H
authors: Shim
authors: Li
authors: L
authors: Wei
authors: Chad A
authors: CA
authors: Holder
authors: Ying
authors: Y
authors: Guo
authors: Xiaoping P
authors: XP
authors: Hu
authors: Andrew H
authors: AH
authors: Miller
authors: Jeffrey J
authors: JJ
authors: Olson
mesh_terms: D001923:Brain Chemistry; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D005909:Glioblastoma / Q000188:drug therapy* / Q000473:pathology*; D056572:Histone Deacetylase Inhibitors / Q000627:therapeutic use*; D006801:Humans; D009682:Magnetic Resonance Spectroscopy / Q000379:methods*
chemical_list: D056572:Histone Deacetylase Inhibitors
keywords: MR spectroscopic imaging; epigenetic modification; glioblastoma; histone deacetylase (HDAC); vorinostat